C57BL/6JCya-Pasd1em1/Cya
Common Name
Pasd1-KO
Product ID
S-KO-18341
Backgroud
C57BL/6JCya
Strain ID
KOCMP-382221-Pasd1-B6J-VA
Status
When using this mouse strain in a publication, please cite “Pasd1-KO Mouse (Catalog S-KO-18341) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
Basic Information
Strain Name
Pasd1-KO
Strain ID
KOCMP-382221-Pasd1-B6J-VA
Gene Name
Pasd1
Product ID
S-KO-18341
Gene Alias
Gm1141
Background
C57BL/6JCya
Gene Full Name
--
Modification
Conventional knockout
NCBI ID
Phenotype
Chromosome
Chr X (Mouse)
Application
--
Datasheet
Strain Description
Ensembl Transcript ID
ENSMUST00000154780
NCBI Transcript ID
--
Target Region
Exon 3~15
Size of Effective Region
~16.6 kb
Overview of Gene Research
PASD1, or Per ARNT Sim domain containing 1, is a cancer-testis antigen. It has been shown to interact with the CLOCK:BMAL1 complex to repress transcriptional activation, thus suppressing circadian rhythms in cells [5]. PASD1 also promotes the activity of the transcription factor STAT3, which is involved in cell proliferation, survival, and differentiation, and aberrant STAT3 activation is related to tumorigenesis [3].
In multiple types of cancers, PASD1 shows potential as an immunotherapeutic target. In colorectal cancer, PASD1 mRNA and protein are expressed in a certain proportion of samples, and specific PASD1 peptides can trigger immunogenic responses, with CD8+ T cells against these peptides able to lyze HLA-A*24:02+ PASD1+ cells [1]. Similar immunogenicity and cytotoxicity effects are seen in CRC and polyps, with different peptides being most immunogenic in each [2]. In diffuse large B-cell lymphoma and multiple myeloma, PASD1-related peptides can induce CD4-positive T-helper cell and cytotoxic T-lymphocyte responses, suggesting its potential for immunotherapy [6,7,8]. In glioma, high PASD1 expression is associated with poor prognosis, and knocking down PASD1 inhibits glioma cell proliferation by promoting apoptosis [4].
In conclusion, PASD1 is a cancer-testis antigen with functions in suppressing circadian rhythms and promoting STAT3-mediated tumorigenesis. Its expression in various cancers and the immunogenic responses it elicits suggest its potential as an immunotherapeutic target, and studies on its knockdown in glioma further demonstrate its role in cancer development. The study of PASD1 provides valuable insights into cancer immunotherapy and the understanding of tumorigenesis mechanisms.
References：
1. Soh, Joanne Ec, Abu, Nadiah, Sagap, Ismail, Ab Mutalib, Nurul S, Jamal, Rahman. 2019. Validation of immunogenic PASD1 peptides against HLA-A*24:02 colorectal cancer. In Immunotherapy, 11, 1205-1219. doi:10.2217/imt-2019-0073. https://pubmed.ncbi.nlm.nih.gov/31478431/
2. Sukor, Nur Fazilah, Yahaya, Azyani, Sagap, Ismail, Jamal, Rahman, Johdi, Nor Adzimah. 2022. Cancer testis antigen PASD1 expression and immunogenicity in human colorectal cancer and polyps. In Turkish journal of biology = Turk biyoloji dergisi, 46, 361-374. doi:10.55730/1300-0152.2623. https://pubmed.ncbi.nlm.nih.gov/37529004/
3. Xu, Zhi-Sheng, Zhang, Hong-Xia, Zhang, Yu-Long, Wang, Yan-Yi, Shu, Hong-Bing. 2016. PASD1 promotes STAT3 activity and tumor growth by inhibiting TC45-mediated dephosphorylation of STAT3 in the nucleus. In Journal of molecular cell biology, 8, 221-31. doi:10.1093/jmcb/mjw005. https://pubmed.ncbi.nlm.nih.gov/26892021/
4. Li, Ruoyan, Guo, Mengguo, Song, Laijun. 2019. PAS Domain Containing Repressor 1 (PASD1) Promotes Glioma Cell Proliferation Through Inhibiting Apoptosis In Vitro. In Medical science monitor : international medical journal of experimental and clinical research, 25, 6955-6964. doi:10.12659/MSM.916308. https://pubmed.ncbi.nlm.nih.gov/31558691/
5. Michael, Alicia K, Harvey, Stacy L, Sammons, Patrick J, Banham, Alison H, Partch, Carrie L. 2015. Cancer/Testis Antigen PASD1 Silences the Circadian Clock. In Molecular cell, 58, 743-54. doi:10.1016/j.molcel.2015.03.031. https://pubmed.ncbi.nlm.nih.gov/25936801/
6. Joseph-Pietras, D, Gao, Y, Zojer, N, Savelyeva, N, Sahota, S S. 2010. DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma. In Leukemia, 24, 1951-9. doi:10.1038/leu.2010.196. https://pubmed.ncbi.nlm.nih.gov/20861911/
7. Ait-Tahar, Kamel, Liggins, Amanda P, Collins, Graham P, Banham, Alison H, Pulford, Karen. 2010. CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma. In Haematologica, 96, 78-86. doi:10.3324/haematol.2010.028241. https://pubmed.ncbi.nlm.nih.gov/20851862/
8. Ait-Tahar, Kamel, Liggins, Amanda P, Collins, Graham P, Banham, Alison H, Pulford, Karen. 2009. Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. In British journal of haematology, 146, 396-407. doi:10.1111/j.1365-2141.2009.07761.x. https://pubmed.ncbi.nlm.nih.gov/19552722/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
